Enrique Ocio, MD, PhD, obtained his medical degree from the University of Salamanca in 1999, where he also specialized in Hematology. Between 2005 and 2006, Dr Ocio was a post-doc at Dana Farber Cancer Institute, Harvard University. From 2013 to 2018, Dr Ocio was an associate professor of medicine at the University of Salamanca. He is currently the head of Hematology at the Marqués de Valdecilla University Hospital, Santander, Spain.
Speaking on the development of new clinical trials and drugs for multiple myeloma
Prof. Ocio focuses on developing new clinical trials and drugs, particularly for Multiple Myeloma. His was recently involved in a Phase I/II trial which evaluated the combination of the kinesin spindle protein inhibitor filanesib with pomalidomide and dexamethasone in relapsed or refractory multiple myeloma patients.